• Male or female, Age 18-75 years old;

• Patients with pathologically/histologically confirmed diagnosis of solid tumors (such as advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma) have received at least once systemic standard treatment and disease progressed; or refused/ cannot tolerate the subsequential standard treatment after the first line treatment;

• Must have CLDN18.2-positive tumor expression ≥10% as determined by the CLDN18.2 IHC assay;

• Estimated life expectancy \> 3 months (according to investigator's judgement);

• At least 1 measurable lesion per RECIST 1.1;

• The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

• Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis;

• Patients should have reasonable CBC counts, renal and hepatic functions;

• No other serious diseases (autoimmune diseases or any immune deficiency disease);

⁃ Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception for at least 12-months after T-cell infusion;

⁃ Men must be willing to use effective and reliable method of contraception and are not allowed to donate sperm for at least 12-months after T-cell infusion;

⁃ Voluntarily participate in the research, understand and sign the informed consent.